Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes.
GLP-1受體激動劑治療在肥胖型2型糖尿病成人中的實際世界評估:持續性、依從性和治療慣性。
Diabetes Ther 2023-04-03
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
2 型糖尿病患者開始使用葡萄糖樣肽-1 受體激動劑的臨床特徵、治療模式和持續性:糖尿病前瞻性追蹤登記的回顧性分析。
Diabetes Obes Metab 2023-06-06
The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia.
長期使用葡萄糖樣肽-1受體激動劑(GLP-1RA)對沙特阿拉伯吉達的KAUH糖尿病患者HbA1c和脂質檔案的可能影響:一項回顧性研究。
Diseases 2023-03-30
Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021.
2013年至2021年間糖尿病患者中SGLT-2抑制劑和GLP-1R激動劑的停藥和重新開始情況:全國性研究。
Lancet Reg Health Eur 2023-06-04
Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.
GLP1-RA和SGLT2-I的依從性影響2型糖尿病患者的臨床結果和成本。
Diabetes Metab Res Rev 2024-04-05
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.
肥胖但無糖尿病的商業保險成年人對糖尿病藥物GLP-1受體激動劑的現實世界持續使用和依從性。
J Manag Care Spec Pharm 2024-05-14
Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.
2型糖尿病患者在常規護理中對新型降糖藥物的依從性和持續性。
Diabetes Res Clin Pract 2024-06-14